In addition, NCL promoted cisplatin resistance via the YB1-MDR pathway in cervical cancer which has been reported through the NCL-mediated cell proliferation leading to the attenuation of cancer cell sensitivity to cisplatin. Here, NUCLEOLIN is linked to cervical cancer.